Farhad Ravandi Selected Research

Cytarabine (Cytosar-U)

11/2022	Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
5/2022	Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study.
1/2022	The cure of leukemia through the optimist's prism.
8/2021	Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
1/2021	A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome.
1/2021	Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
9/2019	Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.
11/2018	Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia.
10/2018	Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens.
4/2018	Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Farhad Ravandi Research Topics

Disease

228	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 11/2022 - 02/2004
80	Neoplasms (Cancer) 10/2022 - 02/2005
72	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 05/2022 - 02/2006
71	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 09/2022 - 06/2006
63	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2022 - 11/2002
61	Leukemia 11/2022 - 11/2002
51	Philadelphia Chromosome 09/2022 - 09/2006
33	Acute Promyelocytic Leukemia 01/2022 - 02/2004
20	Residual Neoplasm 01/2021 - 01/2009
17	Infections 01/2022 - 02/2005
15	Hairy Cell Leukemia 01/2022 - 09/2005
13	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 02/2005
13	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 02/2003
12	Blast Crisis (Blast Phase) 01/2021 - 02/2007
12	Chronic Myelomonocytic Leukemia (Leukemia, Chronic Myelomonocytic) 01/2021 - 10/2006
11	Primary Myelofibrosis (Myelosclerosis) 11/2021 - 09/2006
10	Thrombocytopenia (Thrombopenia) 01/2022 - 07/2010
10	Exanthema (Rash) 01/2021 - 06/2009
10	Pathologic Complete Response 12/2020 - 09/2010
9	Chromosome Aberrations (Chromosome Abnormalities) 01/2022 - 02/2006
9	Neutropenia 10/2021 - 05/2004
8	Fatigue 12/2021 - 05/2006
7	Lymphoma (Lymphomas) 01/2021 - 04/2006
7	Hypertension (High Blood Pressure) 12/2020 - 07/2006
6	Disease Progression 01/2021 - 10/2012
6	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2021 - 03/2003
6	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 01/2020 - 08/2013
6	Diarrhea 01/2019 - 09/2006
5	Anemia 01/2022 - 07/2010
5	Pneumonia (Pneumonitis) 01/2022 - 07/2012
5	Mucositis 10/2017 - 07/2006
4	Leukocytosis (Pleocytosis) 01/2022 - 09/2008
4	Hyperbilirubinemia 01/2022 - 10/2008
4	Central Nervous System Diseases (CNS Diseases) 10/2021 - 04/2007

Drug/Important Bio-Agent (IBA)

50	Tyrosine Kinase InhibitorsIBA 09/2022 - 05/2009
49	Cytarabine (Cytosar-U)FDA LinkGeneric 11/2022 - 11/2005
41	Decitabine FDA Link 01/2022 - 03/2003
34	Imatinib Mesylate (Gleevec)FDA Link 11/2019 - 02/2003
30	venetoclaxIBA 11/2022 - 01/2018
23	Dasatinib (BMS 354825)FDA Link 05/2022 - 08/2008
21	Azacitidine (5 Azacytidine)FDA Link 01/2022 - 10/2007
20	Core Binding Factors (Core-Binding Factor)IBA 01/2022 - 12/2008
19	Vincristine (Oncovin)FDA LinkGeneric 10/2021 - 10/2008
17	Cyclophosphamide (Cytoxan)FDA LinkGeneric 10/2021 - 03/2003
16	Arsenic Trioxide (Trisenox)FDA Link 01/2022 - 11/2002
16	Proteins (Proteins, Gene)FDA Link 01/2022 - 11/2002
16	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2022 - 02/2004
16	Dexamethasone (Maxidex)FDA LinkGeneric 11/2021 - 10/2008
16	Clofarabine (Clolar)FDA Link 01/2021 - 07/2006
16	Monoclonal AntibodiesIBA 01/2021 - 09/2005
15	fms-Like Tyrosine Kinase 3IBA 01/2022 - 01/2011
14	Idarubicin (4 Demethoxydaunorubicin)FDA LinkGeneric 08/2021 - 02/2007
13	ponatinibIBA 05/2022 - 04/2015
13	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2021 - 10/2008
12	Pharmaceutical PreparationsIBA 01/2022 - 07/2006
12	Rituximab (Mabthera)FDA Link 01/2022 - 08/2010
12	Phosphotransferases (Kinase)IBA 01/2019 - 11/2002
11	Sorafenib (BAY 43-9006)FDA Link 11/2020 - 12/2008
11	NucleosidesIBA 12/2015 - 09/2005
10	Inotuzumab OzogamicinIBA 01/2022 - 06/2013
9	Cladribine FDA LinkGeneric 11/2022 - 06/2006
9	fludarabineIBA 01/2022 - 12/2008
8	Lenalidomide (CC 5013)FDA Link 10/2022 - 10/2009
8	blinatumomabIBA 09/2022 - 01/2018
8	purineIBA 05/2022 - 09/2005
8	Gemtuzumab (Mylotarg)FDA Link 01/2022 - 02/2009
8	Transaminases (Aminotransferases)IBA 12/2018 - 10/2008
8	Alemtuzumab (Campath)FDA Link 11/2009 - 02/2005
7	AnthracyclinesIBA 05/2022 - 07/2010
7	ruxolitinibIBA 11/2021 - 08/2011
7	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 11/2021 - 08/2013
7	Biological ProductsIBA 01/2021 - 02/2006
7	DNA (Deoxyribonucleic Acid)IBA 10/2020 - 03/2014
7	Pentostatin (Nipent)FDA LinkGeneric 01/2020 - 01/2006
7	Prednisone (Sone)FDA LinkGeneric 12/2018 - 10/2009
6	NucleophosminIBA 01/2021 - 01/2009
6	Tyrosine (L-Tyrosine)FDA Link 10/2019 - 01/2008
6	vosaroxinIBA 11/2018 - 02/2015
6	nilotinib FDA Link 01/2018 - 08/2008
5	CreatinineIBA 01/2022 - 01/2010
5	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 10/2021 - 12/2008
5	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 01/2021 - 12/2011
5	BilirubinIBA 12/2018 - 04/2012
5	Methotrexate (Mexate)FDA LinkGeneric 02/2016 - 04/2007
4	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 05/2015
4	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2022 - 10/2013
4	Biomarkers (Surrogate Marker)IBA 12/2021 - 11/2010

Therapy/Procedure

196	Therapeutics 10/2022 - 02/2003
93	Drug Therapy (Chemotherapy) 11/2022 - 02/2006
19	Stem Cell Transplantation 07/2020 - 02/2005
16	Induction Chemotherapy 09/2022 - 12/2010
13	Salvage Therapy 01/2021 - 07/2007
11	Hematopoietic Stem Cell Transplantation 01/2021 - 05/2006
6	Combination Drug Therapy (Combination Chemotherapy) 01/2019 - 11/2010
5	Immunotherapy 01/2022 - 06/2011
5	Transplantation 01/2021 - 11/2006
4	Remission Induction 10/2022 - 01/2010
4	Radiotherapy 10/2022 - 02/2012
4	Cell Transplantation 01/2022 - 01/2007
4	Drug Tapering 11/2021 - 07/2010